Literature DB >> 22414547

Decreased expression of T-cadherin is associated with gastric cancer prognosis.

YaPing Tang1, YingHuan Dai, JiRong Huo.   

Abstract

BACKGROUND/AIMS: To investigate the expression status of truncated-cadherin (T-cadherin) and its clinicopathological significance in gastric cancer.
METHODOLOGY: Expression status of T-cadherin was detected in a total of 103 surgical specimens of gastric cancer and 34 corresponding normal gastric tissues by real-time qPCR, western blotting and immunohistochemistry. Correlation between the expression of T-cadherin and clinicopathological factors of gastric cancer was analyzed.
RESULTS: T-cadherin mRNA levels were significantly reduced in 29 (85.3%) tumor tissue samples, compared with levels in the adjacent normal tissue samples (p<0.01). This finding was confirmed by western blotting analysis (p<0.01) and immunohistochemistry analysis (p<0.01). Larger tumor size (diameter >4cm), lymph node metastasis, invasion into surrounding tissues, poor-differentiation and higher TNM stage of carcinoma were significantly correlated with decreased expression of T-cadherin (p<0.05 or p<0.01). Univariate Cox regression analysis showed that smaller tumor size (diameter =4cm), none lymph node metastasis, none invasion into surrounding tissues, well-differentiation, lower TNM stage and higher expression of T-cadherin were closely associated with increased overall survival (p<0.05 or p<0.01). Multivariate Cox regression analysis showed that positive expression of T-cadherin was a most important independent risk factor in gastric cancer.
CONCLUSIONS: Expression of T-cadherin is an important independent prognostic predictor, which can be used as a biomarker of progression and prognosis in gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22414547     DOI: 10.5754/hge12016

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  6 in total

1.  Different cellular localization of NF-κB p65 expression as an indicator of different prognoses of stage I-III gastric cancer patients.

Authors:  Fang Zhou; Hongjun Wei; Aiping Ding; Wensheng Qiu; Lingxin Feng; Quan Zhou; Jun Liang; Lu Yue
Journal:  Clin Transl Sci       Date:  2013-05-08       Impact factor: 4.689

2.  Overexpression of stathmin 1 is associated with poor prognosis of patients with gastric cancer.

Authors:  Bin Ke; Liang-Liang Wu; Ning Liu; Ru-Peng Zhang; Chang-Li Wang; Han Liang
Journal:  Tumour Biol       Date:  2013-06-13

3.  T-cadherin is associated with prognosis in triple-negative breast cancer.

Authors:  De-Di Kong; Mei-Hong Wang; Jie Yang; Liang Li; Wei Wang; Shi-Bing Wang; Yan-Zhen Zhou
Journal:  Oncol Lett       Date:  2017-06-30       Impact factor: 2.967

4.  Association of T-cadherin levels with the response to neoadjuvant chemotherapy in locally advanced breast cancer.

Authors:  Dedi Kong; Mei-Hong Wang; Jie Yang; Liang Li
Journal:  Oncotarget       Date:  2017-02-21

5.  Cadherin 13 Inhibits Pancreatic Cancer Progression and Epithelial-mesenchymal Transition by Wnt/β-Catenin Signaling.

Authors:  Dengfei Xu; Hui Yuan; Zihong Meng; Chunmei Yang; Zefang Li; Mengge Li; Zhigang Zhang; Yu Gan; Hong Tu
Journal:  J Cancer       Date:  2020-02-03       Impact factor: 4.207

6.  Upregulation of T-cadherin suppresses cell proliferation, migration and invasion of gastric cancer in vitro.

Authors:  Jianqing Lin; Zhiyao Chen; Zhijun Huang; Feng Chen; Zeyi Ye; Shaoze Lin; Weidong Wang
Journal:  Exp Ther Med       Date:  2017-09-01       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.